C4 Therapeutics reported third quarter financial results and highlighted recent achievements in Phase 2 MOMENTUM and Phase 1b trials, showing progress towards data publication in late 2026 and enrollment goals for 2027, which underscores ongoing clinical advancement for its cemsidomide candidate.